Prognostic value of N-terminal pro-brain natriuretic peptide in outpatients with hypertrophic cardiomyopathy

Rossella D'Amato, Benedetta Tomberli, Gabriele Castelli, Roberto Spoladore, Francesca Girolami, Alessandra Fornaro, Anna Caldini, Francesca Torricelli, Paolo Camici, Gian Franco Gensini, Franco Cecchi, Iacopo Olivotto

Research output: Contribution to journalArticle

Abstract

In hypertrophic cardiomyopathy, the plasma levels of N-terminal pro-brain natriuretic peptide (NT-proBNP) correlate with functional capacity. However, their prognostic relevance remains unresolved. We followed up 183 stable outpatients with hypertrophic cardiomyopathy (age 50 ± 17 years, 64% men) for 3.9 ± 2.8 years after NT-proBNP measurement. The primary end point included cardiovascular death, heart transplantation, resuscitated cardiac arrest, and appropriate implantable cardioverter-defibrillator intervention. The secondary end point (SE) included heart failure-related death or hospitalization, progression to end-stage disease, and stroke. The median NT-proBNP level was 615 pg/ml (intertertile range 310 to 1,025). The incidence of the primary end point in the lower, middle, and upper tertiles was 0%, 1.3%, and 2.1% annually, respectively (overall p = 0.01). On multivariate analysis, the only independent predictors of the primary end point were NT-proBNP (hazard ratio for log-transformed values 5.8, 95% confidence interval 1.07 to 31.6; p = 0.04) and a restrictive left ventricular filling pattern (hazard ratio 5.19, 95% confidence interval 1.3 to 21.9; p = 0.02). The NT-proBNP cutoff value of 810 pg/ml had the best sensitivity for the primary end point (88%), but the specificity was low (61%). The incidence of the SE in the lower, middle, and upper NT-proBNP tertiles was 4.6%, 12.0%, and 11.2% annually, respectively (overall p = 0.001). An NT-proBNP level of

Original languageEnglish
Pages (from-to)1190-1196
Number of pages7
JournalThe American Journal of Cardiology
Volume112
Issue number8
DOIs
Publication statusPublished - Oct 15 2013

Fingerprint

Brain Natriuretic Peptide
Hypertrophic Cardiomyopathy
Outpatients
Confidence Intervals
Implantable Defibrillators
Incidence
Heart Transplantation
Heart Arrest
Hospitalization
Multivariate Analysis
Heart Failure
Stroke

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

D'Amato, R., Tomberli, B., Castelli, G., Spoladore, R., Girolami, F., Fornaro, A., ... Olivotto, I. (2013). Prognostic value of N-terminal pro-brain natriuretic peptide in outpatients with hypertrophic cardiomyopathy. The American Journal of Cardiology, 112(8), 1190-1196. https://doi.org/10.1016/j.amjcard.2013.06.018

Prognostic value of N-terminal pro-brain natriuretic peptide in outpatients with hypertrophic cardiomyopathy. / D'Amato, Rossella; Tomberli, Benedetta; Castelli, Gabriele; Spoladore, Roberto; Girolami, Francesca; Fornaro, Alessandra; Caldini, Anna; Torricelli, Francesca; Camici, Paolo; Gensini, Gian Franco; Cecchi, Franco; Olivotto, Iacopo.

In: The American Journal of Cardiology, Vol. 112, No. 8, 15.10.2013, p. 1190-1196.

Research output: Contribution to journalArticle

D'Amato, R, Tomberli, B, Castelli, G, Spoladore, R, Girolami, F, Fornaro, A, Caldini, A, Torricelli, F, Camici, P, Gensini, GF, Cecchi, F & Olivotto, I 2013, 'Prognostic value of N-terminal pro-brain natriuretic peptide in outpatients with hypertrophic cardiomyopathy', The American Journal of Cardiology, vol. 112, no. 8, pp. 1190-1196. https://doi.org/10.1016/j.amjcard.2013.06.018
D'Amato, Rossella ; Tomberli, Benedetta ; Castelli, Gabriele ; Spoladore, Roberto ; Girolami, Francesca ; Fornaro, Alessandra ; Caldini, Anna ; Torricelli, Francesca ; Camici, Paolo ; Gensini, Gian Franco ; Cecchi, Franco ; Olivotto, Iacopo. / Prognostic value of N-terminal pro-brain natriuretic peptide in outpatients with hypertrophic cardiomyopathy. In: The American Journal of Cardiology. 2013 ; Vol. 112, No. 8. pp. 1190-1196.
@article{1f50a50611914b3b88e28ef0f793e85e,
title = "Prognostic value of N-terminal pro-brain natriuretic peptide in outpatients with hypertrophic cardiomyopathy",
abstract = "In hypertrophic cardiomyopathy, the plasma levels of N-terminal pro-brain natriuretic peptide (NT-proBNP) correlate with functional capacity. However, their prognostic relevance remains unresolved. We followed up 183 stable outpatients with hypertrophic cardiomyopathy (age 50 ± 17 years, 64{\%} men) for 3.9 ± 2.8 years after NT-proBNP measurement. The primary end point included cardiovascular death, heart transplantation, resuscitated cardiac arrest, and appropriate implantable cardioverter-defibrillator intervention. The secondary end point (SE) included heart failure-related death or hospitalization, progression to end-stage disease, and stroke. The median NT-proBNP level was 615 pg/ml (intertertile range 310 to 1,025). The incidence of the primary end point in the lower, middle, and upper tertiles was 0{\%}, 1.3{\%}, and 2.1{\%} annually, respectively (overall p = 0.01). On multivariate analysis, the only independent predictors of the primary end point were NT-proBNP (hazard ratio for log-transformed values 5.8, 95{\%} confidence interval 1.07 to 31.6; p = 0.04) and a restrictive left ventricular filling pattern (hazard ratio 5.19, 95{\%} confidence interval 1.3 to 21.9; p = 0.02). The NT-proBNP cutoff value of 810 pg/ml had the best sensitivity for the primary end point (88{\%}), but the specificity was low (61{\%}). The incidence of the SE in the lower, middle, and upper NT-proBNP tertiles was 4.6{\%}, 12.0{\%}, and 11.2{\%} annually, respectively (overall p = 0.001). An NT-proBNP level of",
author = "Rossella D'Amato and Benedetta Tomberli and Gabriele Castelli and Roberto Spoladore and Francesca Girolami and Alessandra Fornaro and Anna Caldini and Francesca Torricelli and Paolo Camici and Gensini, {Gian Franco} and Franco Cecchi and Iacopo Olivotto",
year = "2013",
month = "10",
day = "15",
doi = "10.1016/j.amjcard.2013.06.018",
language = "English",
volume = "112",
pages = "1190--1196",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "8",

}

TY - JOUR

T1 - Prognostic value of N-terminal pro-brain natriuretic peptide in outpatients with hypertrophic cardiomyopathy

AU - D'Amato, Rossella

AU - Tomberli, Benedetta

AU - Castelli, Gabriele

AU - Spoladore, Roberto

AU - Girolami, Francesca

AU - Fornaro, Alessandra

AU - Caldini, Anna

AU - Torricelli, Francesca

AU - Camici, Paolo

AU - Gensini, Gian Franco

AU - Cecchi, Franco

AU - Olivotto, Iacopo

PY - 2013/10/15

Y1 - 2013/10/15

N2 - In hypertrophic cardiomyopathy, the plasma levels of N-terminal pro-brain natriuretic peptide (NT-proBNP) correlate with functional capacity. However, their prognostic relevance remains unresolved. We followed up 183 stable outpatients with hypertrophic cardiomyopathy (age 50 ± 17 years, 64% men) for 3.9 ± 2.8 years after NT-proBNP measurement. The primary end point included cardiovascular death, heart transplantation, resuscitated cardiac arrest, and appropriate implantable cardioverter-defibrillator intervention. The secondary end point (SE) included heart failure-related death or hospitalization, progression to end-stage disease, and stroke. The median NT-proBNP level was 615 pg/ml (intertertile range 310 to 1,025). The incidence of the primary end point in the lower, middle, and upper tertiles was 0%, 1.3%, and 2.1% annually, respectively (overall p = 0.01). On multivariate analysis, the only independent predictors of the primary end point were NT-proBNP (hazard ratio for log-transformed values 5.8, 95% confidence interval 1.07 to 31.6; p = 0.04) and a restrictive left ventricular filling pattern (hazard ratio 5.19, 95% confidence interval 1.3 to 21.9; p = 0.02). The NT-proBNP cutoff value of 810 pg/ml had the best sensitivity for the primary end point (88%), but the specificity was low (61%). The incidence of the SE in the lower, middle, and upper NT-proBNP tertiles was 4.6%, 12.0%, and 11.2% annually, respectively (overall p = 0.001). An NT-proBNP level of

AB - In hypertrophic cardiomyopathy, the plasma levels of N-terminal pro-brain natriuretic peptide (NT-proBNP) correlate with functional capacity. However, their prognostic relevance remains unresolved. We followed up 183 stable outpatients with hypertrophic cardiomyopathy (age 50 ± 17 years, 64% men) for 3.9 ± 2.8 years after NT-proBNP measurement. The primary end point included cardiovascular death, heart transplantation, resuscitated cardiac arrest, and appropriate implantable cardioverter-defibrillator intervention. The secondary end point (SE) included heart failure-related death or hospitalization, progression to end-stage disease, and stroke. The median NT-proBNP level was 615 pg/ml (intertertile range 310 to 1,025). The incidence of the primary end point in the lower, middle, and upper tertiles was 0%, 1.3%, and 2.1% annually, respectively (overall p = 0.01). On multivariate analysis, the only independent predictors of the primary end point were NT-proBNP (hazard ratio for log-transformed values 5.8, 95% confidence interval 1.07 to 31.6; p = 0.04) and a restrictive left ventricular filling pattern (hazard ratio 5.19, 95% confidence interval 1.3 to 21.9; p = 0.02). The NT-proBNP cutoff value of 810 pg/ml had the best sensitivity for the primary end point (88%), but the specificity was low (61%). The incidence of the SE in the lower, middle, and upper NT-proBNP tertiles was 4.6%, 12.0%, and 11.2% annually, respectively (overall p = 0.001). An NT-proBNP level of

UR - http://www.scopus.com/inward/record.url?scp=84884907415&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884907415&partnerID=8YFLogxK

U2 - 10.1016/j.amjcard.2013.06.018

DO - 10.1016/j.amjcard.2013.06.018

M3 - Article

C2 - 23871673

AN - SCOPUS:84884907415

VL - 112

SP - 1190

EP - 1196

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 8

ER -